Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, Tajima Y, Ardeleanu M, Rizova E, Arima K; ADDRESS-J Investigators. Katoh N, et al. Among authors: rizova e. J Dermatol. 2019 Apr;46(4):290-300. doi: 10.1111/1346-8138.14787. Epub 2019 Feb 13. J Dermatol. 2019. PMID: 30756423 Free PMC article.
Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry.
Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, Fujita H, Ardeleanu M, Rizova E, Arima K; ADDRESS-J Investigators. Katoh N, et al. Among authors: rizova e. J Dermatol. 2022 Sep;49(9):903-911. doi: 10.1111/1346-8138.16485. Epub 2022 Jun 17. J Dermatol. 2022. PMID: 35715964 Free PMC article.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B. Silverberg JI, et al. Among authors: rizova e. Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11. Br J Dermatol. 2019. PMID: 30791102 Free PMC article. Clinical Trial.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Wollenberg A, et al. Among authors: rizova e. Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1. Br J Dermatol. 2020. PMID: 31407311 Free PMC article.
Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.
Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP, Ferrucci SM, Arenberger P, Svensson A, Schuttelaar MLA, Nosbaum A, Jayawardena S, Rizova E, Ardeleanu M, Eckert L, Ozturk ZE. Bruin-Weller M, et al. Among authors: rizova e. J Dermatolog Treat. 2021 Mar;32(2):164-173. doi: 10.1080/09546634.2020.1866741. Epub 2021 Jan 18. J Dermatolog Treat. 2021. PMID: 33461356
Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry.
Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, Antila M, de Bruin-Weller MS, Marcoux D, Abramova A, Rizova E, Liu C, Zhang A. Paller AS, et al. Among authors: rizova e. J Am Acad Dermatol. 2022 Nov;87(5):1104-1108. doi: 10.1016/j.jaad.2022.01.018. Epub 2022 Jan 23. J Am Acad Dermatol. 2022. PMID: 35081419 Free article. No abstract available.
Conjunctivitis in dupilumab clinical trials.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Akinlade B, et al. Among authors: rizova e. Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology.
Paller AS, Guttman-Yassky E, Irvine AD, Baselga E, de Bruin-Weller M, Jayawardena S, Zhang A, Mina-Osorio P, Rizova E, Ozturk ZE. Paller AS, et al. Among authors: rizova e. BMJ Open. 2020 Mar 24;10(3):e033507. doi: 10.1136/bmjopen-2019-033507. BMJ Open. 2020. PMID: 32209624 Free PMC article.
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L. Ariëns LFM, et al. Among authors: rizova e. Acta Derm Venereol. 2019 Sep 1;99(10):851-857. doi: 10.2340/00015555-3219. Acta Derm Venereol. 2019. PMID: 31099402 Free article.
18 results